

PUBLIC ANNOUNCEMENT



KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED

Our Company was incorporated as 'Jagjit Singh and Sons Private Limited', a private limited company under the Companies Act, 1956, with a certificate of incorporation issued by the Registrar of Companies, Maharashtra at Mumbai on July 26, 1973. Our Company changed the location of its registered office from the State of Maharashtra to the erstwhile State of Andhra Pradesh, pursuant to an order dated January 29, 2003 by the Company Law Board, Western Region Bench, Mumbai ("Order") and the registration of the Order vide certificate of registration dated February 21, 2003 by the Registrar of Companies, Andhra Pradesh and Telangana (then the Registrar of Companies, Andhra Pradesh) ("RoC"). Subsequently, the name of our Company was changed to 'Krishna Institute of Medical Sciences Private Limited', pursuant to a letter of approval from the Central Government dated January 2, 2004 and a fresh certificate of incorporation issued by the RoC on January 2, 2004. Further, pursuant to the conversion of our Company to a public limited company, our name was changed to 'Krishna Institute of Medical Sciences Limited' and the RoC issued a fresh certificate of incorporation on January 29, 2004. For further details, see "*History and Certain Corporate Matters*" beginning on page 186 of the draft red herring prospectus dated February 26, 2021 ("DRHP").

**Registered and Corporate Office:** D. No. 1-8-31/1, Minister's Road, Secunderabad - 3, Telangana - 500 003, India; **Tel:** +91 40 4418 6000; **Website:** www.kimshospitals.com; **Contact Person:** Umashankar Mantha, Company Secretary and Compliance Officer; **E-mail:** cs@kimshospitals.com; **Corporate Identity Number:** U55101TG1973PLC040558

OUR PROMOTERS: DR. BHASKARA RAO BOLLINENI, RAJYASRI BOLLINENI, DR. ABHINAY BOLLINENI, ADWIK BOLLINENI AND BOLLINENI RAMANAIAH MEMORIAL HOSPITALS PRIVATE LIMITED

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹10 EACH ("EQUITY SHARES") OF KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED ("COMPANY" OR "ISSUER") FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[●] PER EQUITY SHARE) (THE "OFFER PRICE") AGGREGATING UP TO ₹[●] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹2,000.00 MILLION (THE "FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 21,340,931 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION (THE "OFFER FOR SALE"), COMPRISING UP TO 13,977,991 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY GENERAL ATLANTIC SINGAPORE KH PTE. LTD (THE "INVESTOR SELLING SHAREHOLDER"), UP TO 775,933 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY DR. BHASKARA RAO BOLLINENI, UP TO 1,163,899 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY RAJYASRI BOLLINENI, UP TO 387,966 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY BOLLINENI RAMANAIAH MEMORIAL HOSPITALS PRIVATE LIMITED (COLLECTIVELY, THE "PROMOTER SELLING SHAREHOLDERS"), 5,035,142 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY PERSONS REFERRED TO IN ANNEXURE A ON PAGE 417 OF THE DRHP (REFERRED TO AS THE "OTHER SELLING SHAREHOLDERS", TOGETHER WITH THE INVESTOR SELLING SHAREHOLDER AND PROMOTER SELLING SHAREHOLDERS, THE "SELLING SHAREHOLDERS", AND SUCH EQUITY SHARES THE "OFFERED SHARES").

THE OFFER INCLUDES A RESERVATION OF UP TO [●] EQUITY SHARES, AGGREGATING UP TO ₹[●] MILLION (CONSTITUTING UP TO [●]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL), FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS "NET OFFER". THE OFFER AND NET OFFER SHALL CONSTITUTE [●]% AND [●]%, RESPECTIVELY, OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE PRICE BAND AND THE MINIMUM BID LOT SHALL BE DECIDED BY THE BOARD OF DIRECTORS OF OUR COMPANY ("OUR BOARD") OR THE IPO COMMITTEE, AS APPLICABLE IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS ("BRLMs") AND WILL BE ADVERTISED IN ALL EDITIONS OF [●] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER), ALL EDITIONS OF [●] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER) AND ALL EDITIONS OF [●] (A WIDELY CIRCULATED TELUGU DAILY NEWSPAPER) (TELUGU BEING THE REGIONAL LANGUAGE IN THE STATE WHERE OUR REGISTERED AND CORPORATE OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO BSE LIMITED ("BSE") AND THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE", AND TOGETHER WITH BSE, THE "STOCK EXCHANGES") FOR THE PURPOSES OF UPLOADING ON THEIR RESPECTIVE WEBSITES IN ACCORDANCE WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE "SEBI ICDR REGULATIONS").

In case of any revision in the Price Band, the Bid/Offer Period will be extended by at least three additional Working Days after revision of the Price Band, subject to the Bid/Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, for reasons to be recorded in writing, extend the Bid/Offer Period for a minimum of three Working Days, subject to the Bid/Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a press release, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the members of the Syndicate and by an intimation to Designated Intermediaries and the Sponsor Bank, as applicable.

The Offer is being made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 31 of the SEBI ICDR Regulations. The Offer is being made through the Book Building Process, in compliance with Regulation 6(2) of the SEBI ICDR Regulations, wherein not less than 75% of the Net Offer will be Allotted on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Board or the IPO Committee, as applicable, may, in consultation with the BRLMs, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the price at which allocation is made to Anchor Investors ("Anchor Investor Allocation Price"). Further, 5% of the Net QIB Portion (excluding the Anchor Investor Portion) shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIBs (excluding the Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. If at least 75% of the Offer cannot be Allotted to QIBs, then the entire application money will be refunded forthwith. Further, not more than 15% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors and not more than 10% of the Net Offer shall be available for allocation to Retail Individual Bidders ("RIBs"), in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. Further, Equity Shares may be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RIBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see "*Offer Procedure*" beginning on page 386 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares pursuant to the Offer and has filed the DRHP with the Securities and Exchange Board of India ("SEBI") on February 26, 2021. Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI shall be made public for comments, if any, for a period of at least 21 days from the date of such filing by hosting it on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges at www.nseindia.com, www.bseindia.com, and the websites of the BRLMs i.e. Kotak Mahindra Capital Company Limited, Axis Capital Limited, Credit Suisse Securities (India) Private Limited and IIFL Securities Limited at www.investmentbank.kotak.com, www.axiscapital.co.in, https://www.credit-suisse.com/in/en/investment-banking/regional-presence/asia-pacific/india/ipo.html and www.iiflcap.com, respectively. Our Company invites the public to give their comments on the DRHP filed with SEBI, with respect to disclosures made in the DRHP. The members of the public are requested to send a copy of the comments sent to SEBI, to the Company Secretary and Compliance Officer of our Company and/or the BRLMs at their respective addresses mentioned below. All comments must be received by our Company and/or the Company Secretary and Compliance Officer or the BRLMs at their respective addresses mentioned herein below in relation to the Offer on or before 5.00 p.m. on the 21<sup>st</sup> day from the aforesaid date of filing of the DRHP with SEBI.

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the DRHP. Specific attention of the investors is invited to "*Risk Factors*" beginning on page 28 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be taken after the Red Herring Prospectus for the same has been filed with the RoC and must be made solely on the basis of such Red Herring Prospectus, as there may be material changes in the Red Herring Prospectus from the DRHP.

The Equity Shares, when offered through the Red Herring Prospectus, are proposed to be listed on BSE and NSE.

For details of the share capital and capital structure of the Company, see "*Capital Structure*" beginning on page 73 of the DRHP. For details of the main objects of the Company as contained in the Memorandum of Association, see "*History and Certain Corporate Matters*" beginning on page 186 of the DRHP.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE OFFER
<b>Kotak Mahindra Capital Company Limited</b> 27 BKC, 1 <sup>st</sup> Floor, Plot No. C – 27, 'G' Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051, Maharashtra, India <b>Tel:</b> +91 22 4336 0000 <b>E-mail:</b> kims.ipo@kotak.com <b>Website:</b> www.investmentbank.kotak.com <b>Investor Grievance ID:</b> kmccredressal@kotak.com <b>Contact Person:</b> Ganesh Rane <b>SEBI Registration Number:</b> INM000008704	<b>Axis Capital Limited</b> 1 <sup>st</sup> Floor, Axis House, C-2, Wadia International Centre, P.B. Marg, Worli, Mumbai 400 025 Maharashtra, India <b>Tel:</b> +91 22 4325 2183 <b>E-mail:</b> kims.ipo@axiscap.in <b>Website:</b> www.axiscapital.co.in <b>Investor Grievance ID:</b> complaints@axiscap.in <b>Contact Person:</b> Ankit Bhatia <b>SEBI Registration Number:</b> INM000012029	<b>Credit Suisse Securities (India) Private Limited</b> Ceejay House, 10 <sup>th</sup> Floor, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai 400 018, Maharashtra, India <b>Tel:</b> +91 22 6777 3777 <b>E-mail:</b> list.kimsipo@credit-suisse.com <b>Website:</b> https://www.credit-suisse.com/in/en/investment-banking/regional-presence/asia-pacific/india/ipo.html <b>Investor Grievance ID:</b> list.igcellmerbnkg@credit-suisse.com <b>Contact Person:</b> Chunky Shah <b>SEBI Registration Number:</b> INM000011161	<b>IIFL Securities Limited</b> 10 <sup>th</sup> Floor, IIFL Centre, Kamala City, Senapati Bapat Marg, Lower Parel (West), Mumbai 400 013, Maharashtra, India <b>Tel:</b> +91 22 4646 4600 <b>E-mail:</b> kims.ipo@iiflcap.com <b>Website:</b> www.iiflcap.com <b>Investor Grievance ID:</b> ig.ib@iiflcap.com <b>Contact person:</b> Shirish Chikalge/ Keyur Ladhawala <b>SEBI Registration Number:</b> INM000010940	<b>KFin Technologies Private Limited<sup>#</sup></b> Selenium Building, Tower B, Plot No. 31-32 Financial District, Nanakramguda, Hyderabad, Rangareddi - 500 032, Telangana, India <b>Tel:</b> + 91 40 6716 2222 <b>E-mail:</b> einward.ris@karvy.com <b>Website:</b> www.kfintech.com <b>Investor Grievance ID:</b> einward.ris@kfintech.com <b>Contact Person:</b> M. Murali Krishna <b>SEBI Registration Number:</b> INR000000221 <sup>#Formerly known as Karvy Fintech Private Limited</sup>

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For Krishna Institute of Medical Sciences Limited  
On behalf of the Board of Directors  
Sd/-  
Company Secretary and Compliance Officer

Place: Secunderabad  
Date: February 27, 2021

KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed a DRHP with SEBI. The DRHP will be available on the website of SEBI at www.sebi.gov.in, NSE at www.nseindia.com, BSE at www.bseindia.com and is available on the websites of the book running lead managers, i.e. Kotak Mahindra Capital Company Limited, Axis Capital Limited, Credit Suisse Securities (India) Private Limited and IIFL Securities Limited at www.investmentbank.kotak.com, www.axiscapital.co.in, https://www.credit-suisse.com/in/en/investment-banking/regional-presence/asia-pacific/india/ipo.html and www.iiflcap.com, respectively. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "*Risk Factors*" beginning on page 28 of the DRHP. Potential investors should not rely on the DRHP for making any investment decision.

This is not an offer of securities for sale in the United States. The Equity Shares may not be offered or sold in the United States absent registration or an exemption from registration. No public offering of the Equity Shares will be made in the United States. The Equity Shares are being offered in offshore transactions outside the United States in compliance with Regulation S under the US Securities Act and in the United States to qualified institutional buyers (as defined in Rule 144A of the US Securities Act) in transactions exempt from or not subject to the registration requirements of the US Securities Act.